AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29980878 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring by a nephrologist at day 90 and every year for 3 years after AKI recovery.
Number of subjects: 1200
Study 29980878 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuminuria and eGFR monitoring.
Number of subjects: 1200
Study 29980878 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of a prediction score for CKD.
Number of subjects: 1200
Study 29980894 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 900 at 40 mg/day with G-CSF
Number of subjects: 29
Study 29980894 — intervention group
Group type: COMPARATOR
Intervention: AMG 900
Number of subjects: 29
Study 29980907 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy and axillary dissection
Number of subjects: 488
Study 29980976 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-ERCP indomethacin
Number of subjects: 790
Study 29981024 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracellular vesicle (EV) RNA sequencing
Number of subjects: 42
Study 29981205 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + 1% MtF gel
Number of subjects: 90
Study 29981205 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + AV gel
Number of subjects: 90
Study 29981205 — intervention group
Group type: COMPARATOR
Intervention: SRP + placebo gel
Number of subjects: 90
Study 29981298 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab treatment
Number of subjects: 103
Study 29981314 — intervention group
Group type: EXPERIMENTAL
Intervention: STand Up Frequently From Stroke (STUFFS) intervention
Number of subjects: 34
Study 29981568 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes shared medical appointments (SMAs)
Number of subjects: 28
Study 29981568 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-to-Peer (P2P) support program
Number of subjects: 28
Study 29981575 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic intersphincteric resection (Lap ISR) with intraoperative radiotherapy using low-energy X-rays (Intrabeam XRS)
Number of subjects: 1
Study 29981580 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD-enriched Cannabis herbal extract
Number of subjects: 28
Study 29981848 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal photopheresis (ECP)
Number of subjects: 77
Study 29982198 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased strength of fetal movements
Number of subjects: 1024
Study 29982198 — intervention group
Group type: COMPARATOR
Intervention: Decreased frequency of fetal movements (without increase in strength)
Number of subjects: 1024
Study 29982198 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily perception of fetal hiccups
Number of subjects: 1024
Study 29982213 — intervention group
Group type: EXPERIMENTAL
Intervention: Sipjeondaebo-tang (3g three times a day for 56 days)
Number of subjects: 48
Study 29982213 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3g three times a day for 56 days)
Number of subjects: 48
Study 29982215 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative acute covert stroke
Number of subjects: 0
Study 29982215 — intervention group
Group type: COMPARATOR
Intervention: Montreal Cognitive Assessment (MoCA) before surgery
Number of subjects: 0
Study 29982215 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain MRI study between postoperative days 2 and 9
Number of subjects: 0
Study 29982215 — intervention group
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA) one year after surgery
Number of subjects: 0
Study 29982217 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propranolol-hydrochloride (1.6 mg/kg/day in three to four divided dosages) until discharge, for a maximum of 10 weeks.
Number of subjects: 0
Study 29982217 — intervention group
Group type: COMPARATOR
Intervention: Placebo until discharge, for a maximum of 10 weeks.
Number of subjects: 0
Study 29982218 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (single oral dose at months 6, 9, 12, and 15)
Number of subjects: 1188
Study 29982218 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitazoxanide (3-day course at months 12 and 15)
Number of subjects: 1188
Study 29982218 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide (daily oral dose given to mother for breastfeeding children aged 0-6 months and directly to children aged 6-18 months)
Number of subjects: 1188
Study 29982218 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen breath assessment
Number of subjects: 1188
Study 29982218 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of cognitive development
Number of subjects: 1188
Study 29982218 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastmilk content of nicotinamide, other vitamins and amino acids
Number of subjects: 1188
Study 29982218 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood measures of tryptophan-kynurenine-niacin pathway
Number of subjects: 1188
Study 29982218 — intervention group
Group type: EXPERIMENTAL
Intervention: Stool pathogens
Number of subjects: 1188
Study 29982223 — intervention group
Group type: EXPERIMENTAL
Intervention: T-SPOT.TB
Number of subjects: 10740
Study 29982223 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculin skin test
Number of subjects: 10740
Study 29982223 — intervention group
Group type: EXPERIMENTAL
Intervention: QuantiFERON
Number of subjects: 10740
Study 29982223 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent TB infection prevalence
Number of subjects: 10740
Study 29982267 — intervention group
Group type: EXPERIMENTAL
Intervention: Households with a member with previously diagnosed hypertension
Number of subjects: 29074
Study 29982267 — intervention group
Group type: COMPARATOR
Intervention: Overall population sodium intake
Number of subjects: 29074
Study 29982279 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant anti-PD-1 (nivolumab)
Number of subjects: 20
Study 29982344 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk score (GRS) of obesity
Number of subjects: 768
Study 29982344 — intervention group
Group type: EXPERIMENTAL
Intervention: Disinhibition
Number of subjects: 768
Study 29982344 — intervention group
Group type: EXPERIMENTAL
Intervention: Susceptibility to hunger
Number of subjects: 768
Study 29982344 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual susceptibility to disinhibition
Number of subjects: 768
Study 29982344 — intervention group
Group type: EXPERIMENTAL
Intervention: Situational susceptibility to disinhibition
Number of subjects: 768
Study 29982344 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal locus of hunger
Number of subjects: 768
Study 29982344 — intervention group
Group type: EXPERIMENTAL
Intervention: External locus of hunger
Number of subjects: 768
Study 29982449 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusions using flucloxacillin
Number of subjects: 150
Study 29982449 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusions using cefepime
Number of subjects: 150
Study 29982449 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusions using vancomycin
Number of subjects: 150
Study 29982449 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusions using piperacillin/tazobactam
Number of subjects: 150
Study 29982449 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusions
Number of subjects: 150
Study 29982514 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivmecillinam 200 mg three times daily for ≤5 days
Number of subjects: 162
Study 29982514 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivmecillinam 400 mg three times daily
Number of subjects: 162
Study 29982518 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV group (N = 922)
Number of subjects: 2459
Study 29982518 — intervention group
Group type: EXPERIMENTAL
Intervention: CHB group (N = 777)
Number of subjects: 2459
Study 29982518 — intervention group
Group type: COMPARATOR
Intervention: Reference group (N = 760)
Number of subjects: 2459
Study 29982620 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake during basic combat training
Number of subjects: 587
Study 29982620 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D intake
Number of subjects: 587
Study 29982620 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleic and α-linolenic acid, fiber, vitamin E, magnesium, potassium intake (males)
Number of subjects: 587
Study 29982620 — intervention group
Group type: EXPERIMENTAL
Intervention: α-linolenic acid, fiber, vitamin E, calcium, iron, magnesium, potassium intake (females)
Number of subjects: 587
Study 29982620 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat and sodium intake
Number of subjects: 587
Study 29982724 — intervention group
Group type: EXPERIMENTAL
Intervention: AHEI-2010
Number of subjects: 57078
Study 29982724 — intervention group
Group type: EXPERIMENTAL
Intervention: aMED
Number of subjects: 57078
Study 29982724 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH
Number of subjects: 57078
Study 29982724 — intervention group
Group type: EXPERIMENTAL
Intervention: HDI
Number of subjects: 57078
Study 29982738 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training interventions, specific details not available
Number of subjects: 0
Study 29983087 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib (PARP inhibitor)
Number of subjects: 34
Study 29983355 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivacaftor treatment for 3 months
Number of subjects: 22
Study 29983597 — intervention group
Group type: EXPERIMENTAL
Intervention: RIG-C (20 IU/kg IM)
Number of subjects: 12
Study 29983992 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation therapy (CRT) + Teach the Parent
Number of subjects: 60
Study 29983992 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation therapy (CRT) + contact control (Family Fun Time)
Number of subjects: 60
Study 29983992 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 60
Study 29983993 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Coping Skills group intervention for HCV (CBCS-HCV)
Number of subjects: 0
Study 29983993 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 29984044 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone therapy as an adjunct to sterile saline
Number of subjects: 41
Study 29984044 — intervention group
Group type: COMPARATOR
Intervention: Sterile saline alone
Number of subjects: 41
Study 29984062 — intervention group
Group type: EXPERIMENTAL
Intervention: PREP-GC (Postoperative Recovery Exercise Program)
Number of subjects: 24
Study 29984589 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional literacy and education
Number of subjects: 0
Study 29984608 — intervention group
Group type: EXPERIMENTAL
Intervention: Overused drug withdrawal with optional preventive medication
Number of subjects: 475
Study 29985674 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular embolization of tributaries of the internal iliac veins
Number of subjects: 0
Study 29985747 — intervention group
Group type: EXPERIMENTAL
Intervention: t-SCNC detection
Number of subjects: 202
Study 29985747 — intervention group
Group type: EXPERIMENTAL
Intervention: small-cell-like cluster
Number of subjects: 202
Study 29985747 — intervention group
Group type: EXPERIMENTAL
Intervention: t-SCNC transcriptional signature
Number of subjects: 202
Study 29985987 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 961
Study 29985987 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 961
Study 29986029 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking 1 cup of coffee per day
Number of subjects: 63257
Study 29986029 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking ≥2 cups of coffee per day
Number of subjects: 63257
Study 29986029 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking ≥2 cups of coffee per day (men)
Number of subjects: 63257
Study 29986029 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking ≥2 cups of coffee per day (women)
Number of subjects: 63257
Study 29986029 — intervention group
Group type: COMPARATOR
Intervention: Tea, soda, or total caffeine consumption
Number of subjects: 63257
Study 29986085 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate (Xyrem) oral solution, median dose 4.5 g per night at start, 6 g per night throughout study, in two equal doses.
Number of subjects: 670
Study 29986669 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient QoL-AD evaluation
Number of subjects: 123
Study 29986669 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver evaluations
Number of subjects: 123
Study 29986669 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall evaluation
Number of subjects: 123
Study 29986672 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminder (weekly)
Number of subjects: 0
Study 29986672 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no SMS reminder)
Number of subjects: 0
Study 29986691 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine 75 mg/m²
Number of subjects: 10
Study 29986710 — intervention group
Group type: EXPERIMENTAL
Intervention: Major TBI group (AIS head > 2)
Number of subjects: 199
Study 29986710 — intervention group
Group type: COMPARATOR
Intervention: No or mild TBI group (AIS head ≤ 2)
Number of subjects: 199
Study 29986786 — intervention group
Group type: EXPERIMENTAL
Intervention: e-cigarette intervention (6-week free e-cigarettes)
Number of subjects: 50
Study 29986845 — intervention group
Group type: EXPERIMENTAL
Intervention: WelTel short-message service (SMS) mHealth program; participants received mobile phones with unlimited texting and weekly bidirectional text messages for one year
Number of subjects: 85
Study 29986845 — intervention group
Group type: EXPERIMENTAL
Intervention: WelTel short-message service (SMS) mHealth program
Number of subjects: 85
Study 29986852 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide at 10-, 15-, and 20-mg dose levels
Number of subjects: 14
Study 29986852 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide maintenance after salvage with high-dose methotrexate or focal irradiation
Number of subjects: 14
Study 29987139 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination tablet of dolutegravir (50 mg) and rilpivirine (25 mg)
Number of subjects: 0
Study 29987139 — intervention group
Group type: COMPARATOR
Intervention: Separate tablets of dolutegravir and rilpivirine (reference treatment)
Number of subjects: 0
Study 29987139 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination tablet
Number of subjects: 0
Study 29987142 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (10 to 15 mg/kg body weight every 12 h)
Number of subjects: 0
Study 29987605 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-Conserving Therapy (BCT)
Number of subjects: 198
Study 29987806 — intervention group
Group type: EXPERIMENTAL
Intervention: Deceased organ donor management
Number of subjects: 67
Study 29987806 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collection on organ recipients
Number of subjects: 67
Study 29987806 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of case report forms (CRFs)
Number of subjects: 67
Study 29988004 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Diagnostic Test (RDT) based on antigen detection (CL Detect Rapid Test)
Number of subjects: 0
Study 29988503 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive Dexamethasone Treatment
Number of subjects: 0
Study 29988503 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 29988514 — intervention group
Group type: EXPERIMENTAL
Intervention: rasagiline 1 mg/day
Number of subjects: 324
Study 29988514 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 324
Study 29988751 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored telephone and email-based exercise intervention
Number of subjects: 111
Study 29988751 — intervention group
Group type: COMPARATOR
Intervention: No-information control group
Number of subjects: 111
Study 29988921 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (4 doses of 1.3 mg/m2 i.v.)
Number of subjects: 8
Study 29988921 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 8
Study 29989087 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Integrated Care (FICare)
Number of subjects: 0
Study 29989087 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29989515 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior hypogastric nerve block (SHNB)
Number of subjects: 44
Study 29989515 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 44
Study 29989854 — intervention group
Group type: EXPERIMENTAL
Intervention: Ado-trastuzumab emtansine at 3.6 mg/kg intravenously every 3 weeks until progression
Number of subjects: 18
Study 29989911 — intervention group
Group type: EXPERIMENTAL
Intervention: Age/Sex/Gene Expression Score (ASGES) - low (<=15)
Number of subjects: 566
Study 29989911 — intervention group
Group type: COMPARATOR
Intervention: Age/Sex/Gene Expression Score (ASGES) - elevated (>15)
Number of subjects: 566
Study 29991024 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg once daily
Number of subjects: 106
Study 29991428 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I) for 8 weeks (n = 29)
Number of subjects: 45
Study 29991428 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition (n = 16)
Number of subjects: 45
Study 29991629 — intervention group
Group type: EXPERIMENTAL
Intervention: 4CMenB vaccination at baseline
Number of subjects: 0
Study 29991629 — intervention group
Group type: COMPARATOR
Intervention: 4CMenB vaccination at study completion
Number of subjects: 0
Study 29991631 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (US) assessment in addition to clinical examination
Number of subjects: 0
Study 29991631 — intervention group
Group type: COMPARATOR
Intervention: Clinical examination
Number of subjects: 0
Study 29992019 — intervention group
Group type: EXPERIMENTAL
Intervention: Small, dense low-density lipoprotein (sd-LDL)
Number of subjects: 44
Study 29992019 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglycerides
Number of subjects: 44
Study 29992019 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C estimated glomerular filtration rate (CysC eGFR)
Number of subjects: 44
Study 29992019 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycated low-density lipoprotein (g-LDL)
Number of subjects: 44
Study 29992039 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg a day taken orally
Number of subjects: 12
Study 29992039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29992040 — intervention group
Group type: EXPERIMENTAL
Intervention: eRAPID (electronic patient self-Reporting of Adverse-events: Patient Information and aDvice)
Number of subjects: 168
Study 29992040 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 168
Study 29992040 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes using validated questionnaires
Number of subjects: 168
Study 29992040 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff and patient experiences
Number of subjects: 168
Study 29992080 — intervention group
Group type: EXPERIMENTAL
Intervention: IgM antibody specific to pneumococcal surface protein A (PspA)
Number of subjects: 0
Study 29992080 — intervention group
Group type: EXPERIMENTAL
Intervention: IgM antibody specific to an unencapsulated pneumococcal strain
Number of subjects: 0
Study 29992080 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 0
Study 29992241 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg every 2 weeks until disease progression or intolerable toxicity for up to 24 months
Number of subjects: 23
Study 29992241 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 23
Study 29992396 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine Tablets (MAVENCLAD) with treatment postponement in year 2 based on ALC recovery
Number of subjects: 0
Study 29992396 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine Tablets (MAVENCLAD) with treatment algorithm applied
Number of subjects: 0
Study 29992396 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine Tablets (MAVENCLAD)
Number of subjects: 0
Study 29992557 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus plus exemestane
Number of subjects: 299
Study 29992594 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcrestal sinus floor elevation (tSFE) with xenograft and collagen matrix
Number of subjects: 57
Study 29992594 — intervention group
Group type: COMPARATOR
Intervention: Lateral sinus floor elevation (lSFE) with xenograft and membrane
Number of subjects: 57
Study 29992599 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurses' solution-focused communication
Number of subjects: 36
Study 29993892 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal electrocardiography (EECG)
Number of subjects: 0
Study 29993892 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed method to estimate the electrical field projected onto the esophagus
Number of subjects: 0
Study 29993892 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm for estimating time-varying catheter position and projected electrical field
Number of subjects: 0
Study 29996152 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraprocedural cleaning device
Number of subjects: 47
Study 29996726 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg twice daily
Number of subjects: 112
Study 29996829 — intervention group
Group type: EXPERIMENTAL
Intervention: Past-year Alcoholics Anonymous (AA) affiliation
Number of subjects: 168
Study 29996829 — intervention group
Group type: EXPERIMENTAL
Intervention: AA outreach and alternative interventions
Number of subjects: 168
Study 29996829 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized treatment plans
Number of subjects: 168
Study 29996884 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B (co-resection of the vein together with the pancreas)
Number of subjects: 0
Study 29996884 — intervention group
Group type: COMPARATOR
Intervention: Arm A (resection of the splenic vein after isolation from the pancreatic parenchyma)
Number of subjects: 0